Table 4.
Number of NTM clinical strains resistant to drugs in in vitro experiments (N = 108)
| Species/complex | Antimicrobial agents | ||||||
|---|---|---|---|---|---|---|---|
| CLAR | AMK | MOX | LZD | CFX | TBM | ||
| RGM | |||||||
| M. abscessus complex (N = 53, %) | 4 (7.5) | 2 (3.8) | 20 (37.7) | 1 (1.9) | 7 (13.2) | 22 (41.5) | |
| M. fortuitum (N = 17, %) | 2 (11.8) | 1 (5.9) | 1 (5.9) | 0 (0.0) | 3 (17.6) | 13 (76.5) | |
| Species | Antimicrobial agents | ||||||
| CLAR | AMK | MOX | LZD | ||||
| SGM | |||||||
| M. intracellulare (N = 27, %) | 4 (14.8) | 0 (0.0) | 4 (14.8) | 0 (0.0) | |||
| M. avium (N = 8, %) | 1 (12.5) | 0 (0.0) | 2 (25.0) | 0 (0.0) | |||
| CLAR | AMK | MOX | LZD | RIF | MIN | RFB | |
| M. kansasii (N = 3, %) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
RGM, rapidly growing non-tuberculous mycobacteria; SGM, slowly growing non-tuberculous mycobacteria; CLAR, clarithromycin; AMK, amikacin; MOX, moxifloxacin; LZD, linezolid; CFX, cefoxitin; TBM, tobramycin; RIF, rifampicin; MIN, minocycline; RFB, rifabutin.
The data are presented as number (%) unless otherwise specified.